Revolution Medicines

Revolution Medicines and Iambic Therapeutics announced a multi-year collaboration in July 2025 to develop novel drug candidates using AI-driven discovery platforms targeting RAS-addicted cancers.

Revolution Medicines and Summit Therapeutics announced a clinical collaboration to evaluate three RAS(ON) inhibitors in combination with ivonescimab, a PD-1/VEGF bispecific antibody, across multiple solid tumor types.

Revolution Medicines partnered with Royalty Pharma on a $2 billion flexible funding agreement to support global development and commercialization of its RAS(ON) inhibitor portfolio for cancer treatment.

Revolution Medicines has developed RMC-9805, a first-in-class covalent KRAS(G12D)(ON) molecular glue inhibitor that targets the previously "undruggable" KRAS(G12D) mutant using a cyclophilin A-recruiting tricomplex mechanism.

• Revolution Medicines announced new clinical data for zoldonrasib (RMC-9805) showing a 61% objective response rate in patients with KRAS G12D mutant non-small cell lung cancer at the AACR Annual Meeting. • The RAS(ON) G12D-selective inhibitor demonstrated an acceptable safety profile with primarily Grade 1 or 2 adverse events and a favorable mean dose intensity of 98% in the Phase 1 study. • These results build on earlier promising data in pancreatic ductal adenocarcinoma, supporting further evaluation of zoldonrasib as both monotherapy and in combination treatments for these difficult-to-treat cancers.

The American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago will focus on "Unifying Cancer Science and Medicine" with presentations spanning from basic research to practice-changing clinical trials.

• A groundbreaking experimental drug, daraxonrasib by Revolution Medicines, demonstrates encouraging results in treating late-stage pancreatic cancer patients, offering new hope in a traditionally difficult-to-treat disease. • One stage-four pancreatic cancer patient has achieved a remarkable 17-month survival while participating in the clinical trial, significantly exceeding typical survival expectations for advanced cases. • The development represents a potential breakthrough in pancreatic cancer treatment, where current five-year survival rates for late-stage patients stand at only 3%, with median survival under one year.

• Revolution Medicines reports RMC-6236 demonstrates encouraging safety and efficacy in Phase 1/1b trials for pancreatic and lung cancers. • In pancreatic cancer, RMC-6236 monotherapy achieved a median progression-free survival of 8.8 months in KRAS G12X-mutated patients. • For lung cancer, RMC-6236 showed a median PFS of 9.8 months in patients who had undergone immunotherapy and platinum chemotherapy. • Revolution Medicines plans to advance RMC-6236 into Phase 3 trials for both metastatic pancreatic and lung cancers in 2025.

• Tango Therapeutics' TNG462 demonstrates clinical activity in NSCLC and pancreatic cancer, with a 43% ORR in cholangiocarcinoma, showcasing a favorable safety profile. • Tango plans to initiate combination trials of TNG462 with RAS(ON) inhibitors from Revolution Medicines, osimertinib, and pembrolizumab in 1H 2025. • TNG908 shows clinical activity in non-CNS cancers, particularly pancreatic cancer, but development is deprioritized in favor of TNG462 due to its superior profile. • Tango's next-generation brain-penetrant PRMT5 inhibitor, TNG456, is set to begin phase 1/2 trials in 1H 2025, targeting glioblastoma and brain metastases.

RMC-9805, a novel oral RAS(ON) G12D-selective covalent inhibitor, shows encouraging safety and anti-tumor activity in pancreatic cancer patients.